Is Aerie’s Move Sustainable?
Like many other companies in the health care industry, Aerie Pharmaceuticals lives and dies by the FDA's sword.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 247RegenXBio Updates Anticipated Price for IPO
This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.
Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market
According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut of the first biosimilar drug in the United States.
Massive Numbers Aged 20 to 35 Still Go Without Health Insurance
The latest data from the U.S. Census Bureau on poverty, health insurance and income shows an alarming number of people aged 20 to 35 (millennials) are still going without health insurance.
SynCardia Updates Terms for IPO
The expected price range for the SynCardia Systems IPO is $10 to $12 for 2.5 million shares.
Meet the Newest Biotech Collaboration: Amgen and Xencor
Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Intra-Cellular Shares Continue to Climb on Positive Results
Intra-Cellular Therapies announced positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia.
Penumbra and RegenXBio Gearing Up for IPOs
ThinkstockTwo private companies in the healthcare sector, Penumbra Inc. and RegenXBio Inc., are planning on going public in later this week. Both companies have set terms in their filings with the U.S. Securities and Exchange…
Solid Draft Guidance Propels Evoke
Shares of Evoke Pharma rose in the market on Tuesday in the wake of solid draft guidance for its Phase 3 study.
Sientra Updates Terms for Secondary Offering
Sientra has filed with the U.S. Securities and Exchange Commission (SEC) to update the terms for its secondary offering.
How GW Pharma’s Newest Cannabinoid Trial Is a Game Changer
GW Pharmaceuticals is making great strides in the field of medicine with its most recent trial of Cannabidiol in patients with schizophrenia.
Xenoport Rises on Solid Phase 2 Results
Xenoport made waves in Tuesday morning’s premarket trading session on news of positive clinical trial results.
Dimension Therapeutics Gears Up for IPO
Dimension Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Is Raptor Pharma Imploding?
Raptor Pharmaceuticals saw its shares approach its 52-week low in Monday's premarket, after missed results in a Phase 2 study.
This Past Week’s Top 5 Biotech Movers
Over the past week, a few biotech companies made absolutely massive runs with at least 25% gains.